Reducing medication for advanced prostate cancer after good response
Part of Cancer, Kidney & urinary clinical trials.
This trial is for people with advanced prostate cancer who are doing well on their current combination of drugs. It tests whether safely reducing to a single hormone therapy is as effective as continuing the combination, which may mean fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a confirmed type of prostate cancer (called adenocarcinoma) that has spread to other parts of the body or come back after local treatment.
- You are currently receiving hormone therapy (ADT) plus one of these drugs: abiraterone, enzalutamide, apalutamide, or darolutamide — with or without docetaxel chemotherapy.
- You have been on that combination for at least 6–7 months without a pause longer than 30 days.
- Your latest PSA blood test is very low (below 0.2) and a PSMA PET/CT scan shows your cancer has shrunk.
- You are generally able to take care of yourself (ECOG score 0–2) and have adequate organ function.
- You have not had prior treatment with these drugs, chemotherapy (except a short course), or certain radioactive medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether giving prostate removal surgery in addition to standard hormone therapy can help men with advanced prostate cancer that has spread to many places. It aims to see if this combination helps them live longer with a better quality of life.
This trial tests a shorter course of hormone therapy plus targeted radiation for prostate cancer that has spread to a few spots (oligometastatic). The goal is to see if less hormone therapy can still control the cancer effectively.
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
This trial tests a new drug combination (GZ17-6.02) for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the drug can help slow down the cancer.
This trial is for men with prostate cancer that has spread to other parts of the body and is being treated with hormone therapy. It looks at whether a drop in PSA levels after six months can help predict how well the treatment is working.
This study tests whether a shorter course of a newer hormone pill (apalutamide or enzalutamide) works well for men whose prostate cancer has spread to just a few spots and who recently started standard hormone therapy. It may allow you to take medication for less time while still controlling the cancer.
Hear when a new Castration Sensitive Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.